Søgeresultater - David R. Spigel

Refine Results
  1. 1
    Advances in molecular‐based personalized non‐small‐cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance

    Advances in molecular‐based personalized non‐small‐cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance af Robert M. Jotte, David R. Spigel

    Udgivet 2015
    Få fuldtekst Få fuldtekst
    Revisão
    Føj til favoritter
    Saved in:
  2. 2
    Rationale for Chemotherapy, Immunotherapy, and Checkpoint Blockade in SCLC: Beyond Traditional Treatment Approaches

    Rationale for Chemotherapy, Immunotherapy, and Checkpoint Blockade in SCLC: Beyond Traditional Treatment Approaches af David R. Spigel, Mark A. Socinski

    Udgivet 2013
    Få fuldtekst Få fuldtekst
    Revisão
    Føj til favoritter
    Saved in:
  3. 3
    The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer

    The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer af Leora Horn, Martin Reck, David R. Spigel

    Udgivet 2016
    Få fuldtekst Få fuldtekst
    Revisão
    Føj til favoritter
    Saved in:
  4. 4
    Phase II Trial of Paclitaxel, Carboplatin, and Etoposide in Advanced Poorly Differentiated Neuroendocrine Carcinoma: A Minnie Pearl Cancer Research Network Study

    Phase II Trial of Paclitaxel, Carboplatin, and Etoposide in Advanced Poorly Differentiated Neuroendocrine Carcinoma: A Minnie Pearl Cancer Research Network Study af John D. Hainsworth, David R. Spigel, Sharlene Litchy, F. Anthony Greco

    Udgivet 2006
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  5. 5
    Molecular Profiling Diagnosis in Unknown Primary Cancer: Accuracy and Ability to Complement Standard Pathology

    Molecular Profiling Diagnosis in Unknown Primary Cancer: Accuracy and Ability to Complement Standard Pathology af F. Anthony Greco, Wayne J. Lennington, David R. Spigel, John D. Hainsworth

    Udgivet 2013
    Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  6. 6
    Phase II Trial of Bevacizumab and Erlotinib in Carcinomas of Unknown Primary Site: The Minnie Pearl Cancer Research Network

    Phase II Trial of Bevacizumab and Erlotinib in Carcinomas of Unknown Primary Site: The Minnie Pearl Cancer Research Network af John D. Hainsworth, David R. Spigel, C. Farley, Dana S. Thompson, Dianna Shipley, F. Anthony Greco

    Udgivet 2007
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  7. 7
    Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib

    Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib af John D. Hainsworth, Jeffrey A. Sosman, David R. Spigel, Donna L. Edwards, Cara Baughman, Anthony Greco

    Udgivet 2005
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  8. 8
    Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts

    Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts af Martin Reck, Fabrice Barlési, Lucio Crinò, Claudia I. Henschke, Dolores Isla, Susanne Stiebeler, David R. Spigel

    Udgivet 2011
    Få fuldtekst Få fuldtekst
    Revisão
    Føj til favoritter
    Saved in:
  9. 9
    Molecular Profiling in Unknown Primary Cancer: Accuracy of Tissue of Origin Prediction

    Molecular Profiling in Unknown Primary Cancer: Accuracy of Tissue of Origin Prediction af F. Anthony Greco, David R. Spigel, Denise A. Yardley, Mark G. Erlander, Xiaojun Ma, John D. Hainsworth

    Udgivet 2010
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  10. 10
    Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute

    Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the... af John D. Hainsworth, Mark S. Rubin, David R. Spigel, Ralph V. Boccia, Samuel Raby, Raven Quinn, F. Anthony Greco

    Udgivet 2012
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  11. 11
    High Incidence of Cetuximab-Related Infusion Reactions in Tennessee and North Carolina and the Association With Atopic History

    High Incidence of Cetuximab-Related Infusion Reactions in Tennessee and North Carolina and the Association With Atopic History af Bert H. O’Neil, Robert M. Allen, David R. Spigel, Thomas E. Stinchcombe, Dominic T. Moore, Jordan Berlin, Richard M. Goldberg

    Udgivet 2007
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  12. 12
    Paclitaxel/Carboplatin plus Bevacizumab/Erlotinib in the First-Line Treatment of Patients with Carcinoma of Unknown Primary Site

    Paclitaxel/Carboplatin plus Bevacizumab/Erlotinib in the First-Line Treatment of Patients with Carcinoma of Unknown Primary Site af John D. Hainsworth, David R. Spigel, Dana S. Thompson, Patrick Murphy, Cassie M. Lane, David Waterhouse, Yuval Naot, F. Anthony Greco

    Udgivet 2009
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  13. 13
    Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer

    Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer af John D. Hainsworth, David R. Spigel, C. Farley, Dianna Shipley, James D. Bearden, Jitendra G. Gandhi, Gerry Ann Houston, F. Anthony Greco

    Udgivet 2007
    Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  14. 14
    PD1.01 (also presented as P2.46): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057

    PD1.01 (also presented as P2.46): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057 af Richard J. Gralla, David R. Spigel, Bryan Bennett, Fiona Taylor, John R. Penrod, Michael DeRosa, Homa Dastani, Lucinda Orsini, Clarissa Mathias, Martin Reck

    Udgivet 2016
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  15. 15
    P2.46 (also presented as PD1.01): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057

    P2.46 (also presented as PD1.01): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057 af Richard J. Gralla, David R. Spigel, Bryan Bennett, Fiona Taylor, John R. Penrod, Michael DeRosa, Homa Dastani, Lucinda Orsini, Clarissa Mathias, Martin Reck

    Udgivet 2016
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  16. 16
    Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer

    Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer af David R. Spigel, F. Anthony Greco, John D. Zubkus, Patrick Murphy, Ruben A. Saez, C. Farley, Denise A. Yardley, Howard A. Burris, John D. Hainsworth

    Udgivet 2009
    Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  17. 17
    Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial

    Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial af David R. Spigel, P. Townley, David Waterhouse, Fang Ting Liang, İbrahim Adıgüzel, Jane E. Huang, David A. Karlin, Leonardo Faoro, Frank A. Scappaticci, Mark A. Socinski

    Udgivet 2011
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  18. 18
    Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung

    Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung af David R. Spigel, Martin J. Edelman, Kenneth J. O’Byrne, Luis Paz‐Ares, Simonetta Mocci, See Phan, David S. Shames, Dustin Smith, Wei Yu, Virginia Paton, Tony Mok

    Udgivet 2017
    Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  19. 19
    Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort

    Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohor... af Howard A. Burris, Suzanne J. Bakewell, Johanna C. Bendell, Jeffrey R. Infante, Suzanne F. Jones, David R. Spigel, Glen J. Weiss, Ramesh K. Ramanathan, Angela Ogden, Daniel D. Von Hoff

    Udgivet 2016
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  20. 20
    Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

    Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study af John D. Hainsworth, Funda Meric‐Bernstam, Charles Swanton, Herbert I. Hurwitz, David R. Spigel, Christopher J. Sweeney, Howard A. Burris, Ron Bose, Bongin Yoo, Alisha Stein, Mary Beattie, Razelle Kurzrock

    Udgivet 2018
    Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:

Søgeredskaber: